BioDot, Inc
Aysel Heckel currently serves as the Head of Commercial Operations at BioDot, Inc. since July 2025. Prior experience includes the role of Vice President of Sales North America at Astrix from April 2024 to March 2025, where contributions supported scientific IT consulting for various sectors including pharma and biotech. At Benchling from April 2022 to September 2023, Aysel led the Mid-Market Sales team, successfully navigating a reduction in force while exceeding team goals. Previously, Aysel was the VP Sales & Support for North America at Oxford Gene Technology, focusing on molecular genetics reagents from January 2016 to July 2021. Earlier roles include Director of Global Clinical Solutions Sales at QIAGEN, Next Gen Sequencing Segment Manager at Ingenuity Systems, District Sales Manager and Translational Genomics Segment Manager at Illumina, and Sales/Marketing Manager at Roche Diagnostics. Aysel holds a Bachelor’s Degree in Biochemistry from Texas A&M University, earned between 1984 and 1988.
This person is not in any teams
This person is not in any offices
BioDot, Inc
For over 25 years, BioDot has developed proprietary, quantitative technologies for the dispensing of low volumes of fluids (picoliter to microliter) that meet the needs of industrial, life science, diagnostic, and medical products. BioDot is division of ATS Automation - Life Sciences Division On March 24, 1994, BioDot established itself as a company in Southern California with its patented BioJet™, "Drop on Demand", non-contact, dispensing technology. At that time, BioDot focused on using this technology to dispense discrete drops, or a series of drops to form a line. This quantitative, enabling technology was used predominantly in Lateral Flow Test or Flow Through Test applications in the diagnostic marketplace. Over the following years, BioDot expanded its expertise outside of dispensing, and developed lamination and cutting technologies. In parallel, it expanded its application abilities to enable scientists to utilize the quantitative dispensing and develop more sophisticated point of care tests, such as: - Glucose or other Microfluidic Sensors - Immunoblots or Allergy Tests - Cell, DNA, or Protein Arrays - Compound Handling In addition, BioDot developed modular workstations and enabled customers to work in either a "Batch" or "In-Line" Approach, depending on their materials and processes, as well as short and long goals. Now, in our 25th year, BioDot continues to be a leading supplier of system tools for the research, development and commercialization of diagnostic tests. With our continuously expanding product portfolio, BioDot has marketed systems for the development and manufacture of Microfluidics. We also have systems for the Life Sciences and the Molecular & Point of Care Diagnostics. By expanding our global presence with entities in China and the UK/Europe, BioDot has a commitment to fully understand our customer's requirements, globally. #lateralflow, #biosensor, #labonachip, #biochip, #dispensing